New antibody takes aim at psoriasis in first human trial
NCT ID NCT06143371
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called CAN10, an antibody that blocks a protein involved in inflammation. Researchers gave single doses to 80 healthy adults and repeated doses to people with mild to moderate plaque psoriasis to see if it is safe and how the body processes it. The goal was to check safety and tolerability, not yet to prove it works for psoriasis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAN10 (an anti-IL1RAP monoclonal antibody)
- What this could lead to
- If successful, this could lead to a new treatment option for plaque psoriasis by targeting inflammation.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work for psoriasis or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test